Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, reflecting a year-on-year increase of 7.5% [1] - Earnings per share were HKD 0.1141, with an interim dividend proposed at HKD 0.022 per share [1] Revenue Growth Drivers - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with "Qufrile" injection achieving a robust growth of 31.4% and "Buleidining" rising by 12.9% [1] - In the traditional product mix of introduced products, "Fipril" saw a significant growth of 33.3%, regaining its position as the largest contributor after last year's transitional phase [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in driving revenue growth, with "Sodium Dexamethasone Injection" and "Nacogdocevir Calcium Injection" recording growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]